ArticleCost effectiveness and resource allocation : C/E2023

Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial.

Qiuling Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.